Takeda
CompanyJapanFounded 1781
Takeda develops 55 assets, the furthest approved (Actos in type 2 diabetes). Mostly small molecule and protein or enzyme acting on DPP4, AGTR1 and PPARG; based in Japan, founded in 1781.
- 55
- Assets
- Furthest stage
- Approved
- 627
- Trials
- 535
- Signals
Pipeline
55PPAR-gamma agonist improving insulin sensitivity and glycemic control.
Approved, Small molecule, PPARG, type 2 diabetes, diabetes mellitus (Phase 3)
Inhibits DPP-4, increasing incretin activity to enhance glucose-dependent insulin secretion and reduce glucagon secretion.
Approved, Small molecule, DPP4, type 2 diabetes, diabetes mellitus (Phase 3)
Alogliptin and Metformin Fixed-Dose Combination
Fixed-dose combination of DPP-4 inhibitor alogliptin and biguanide metformin.
Approved, Small molecule, type 2 diabetes, diabetes mellitus (Phase 3)
52 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
76 assets, 79 trials
5 assets, 13 trials
3 assets, 10 trials
3 assets
Takeda Pharmaceuticals North America
1 asset
91 trials
4 trials
In the full profile
- Evidence behind the mechanisms10
- Trials972
- Deals7
- Signals20
- Integrity notices2
- Similar companies6
Papers
Journal of epidemiology, May 7, 2026
ADA Scientific Sessions 2025 abstract, Jun 13, 2025
Scientific reports, Nov 7, 2024
The Journal of biological chemistry, Feb 29, 2024
Scientific reports, Jan 20, 2024
BMC genomics, Dec 4, 2021
A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells
Nature communications, Apr 24, 2020
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
Drug safety, Oct 28, 2019
Behavioural brain research, Sep 16, 2019
Deoxysphingolipids and ether-linked diacylglycerols accumulate in the tissues of aged mice
Cell & bioscience, Aug 14, 2019
Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice
Scientific reports, Aug 31, 2016
Scientific reports, May 21, 2016
General and comparative endocrinology, Jul 10, 2013
N-Formylated humanin activates both formyl peptide receptor-like 1 and 2
Biochemical and biophysical research communications, Nov 5, 2004
Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10
Experimental gerontology, Jan 1, 1997
Experimental gerontology, Jan 1, 1997
The Journal of nutrition, Nov 1, 1991